

Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes

To extend understanding of the genetic architecture and molecular basis of type 2 diabetes (T2D), we conducted a meta-analysis of genetic variants on the MetaboChIP, including 34,840 cases and 114,981 controls, overwhelmingly of European descent. We identified ten previously unreported T2D susceptibility loci, including two showing sex-differentiated association. Genome-wide analyses of these data are consistent with a long tail of additional common variant loci explaining much of the variation in susceptibility to T2D. Exploration of the enlarged set of susceptibility loci implicates several processes, including CREBBP-related transcription, adipocytokine signaling and cell cycle regulation, in diabetes pathogenesis.

T2D is a chronic metabolic disease with multifactorial pathogenesis¹. Although the genetic contribution to T2D is well recognized, the current set of 56 established susceptibility loci, identified primarily through large-scale genome-wide association studies (GWAS)^{2–11}, captures at best 10% of familial aggregation of the disease. The characteristics (effect sizes and risk allele frequencies (RAFs)) of the variants contributing to the unexplained genetic variance remain far from clear. At the same time, difficulties in inferring biological mechanisms from the variants of modest effect identified by GWAS have inhibited progress in defining the pathophysiological basis of disease susceptibility. One key question is whether characterization of increasing numbers of risk loci will provide evidence, at the functional level, that susceptibility involves a limited set of molecular processes.

To extend the discovery and characterization of variants influencing T2D susceptibility, we performed large-scale genotyping using the MetaboChIP. This custom array of 196,725 variants was designed to facilitate cost-effective follow-up of nominal associations for T2D and other metabolic and cardiovascular traits and to enhance fine mapping of established loci¹². The T2D component of MetaboChIP comprises 21,774 variants, including 5,057 'replication' SNPs that capture the strongest independent ($r^2 < 0.2$ in 1000 Genomes Project Utah residents of Northern and Western European ancestry (CEU) data)¹³ autosomal association signals from the GWAS meta-analysis conducted by the DIABetes Genetics Replication and Meta-analysis (DIAGRAM) Consortium. This genome-wide meta-analysis (DIAGRAMv3) includes data from 12,171 T2D cases and 56,862 controls of European descent imputed at up to 2.5 million autosomal SNPs and augments the previously published DIAGRAMv2 meta-analysis⁴ with 4 additional GWAS (Supplementary Table 1). The T2D content of MetaboChIP includes an additional 16,717 variants, most chosen from 1000 Genomes Project pilot data¹³, to fine map 27 established susceptibility loci.

RESULTS

Study overview

Our primary investigation combined the DIAGRAMv3 (stage 1) GWAS meta-analysis with a stage 2 meta-analysis comprising 22,669 cases and 58,119 controls genotyped with MetaboChIP, including 1,178 cases and 2,472 controls of Pakistani descent (Pakistan Risk Of Myocardial Infarction Study (PROMIS)) (Online Methods and Supplementary Table 1). There was little evidence of heterogeneity in allelic effects between studies of individuals of European and Pakistani descent in stage 2 (Supplementary Fig. 1); therefore, we report the combined meta-analysis, including PROMIS, with genomic control correction.

T2D susceptibility loci reaching genome-wide significance

Combining stage 1 and stage 2 meta-analyses (Supplementary Fig. 2), we identified eight new T2D susceptibility loci at genome-wide significance ($P < 5 \times 10^{-8}$) (Table 1, Supplementary Fig. 3 and Supplementary Table 2). By convention, we have labeled loci according to the gene nearest to the lead SNP, unless a compelling biological candidate mapped nearby. The strongest signals mapped to *ZMIZ1* ($P = 1.0 \times 10^{-10}$), *ANK1* ($P = 2.5 \times 10^{-10}$) and the region flanking *KLHDC5* ($P = 6.1 \times 10^{-10}$). We also observed associations at genome-wide significance at *HMG20A* ($P = 4.6 \times 10^{-9}$) and *GRB14* ($P = 1.0 \times 10^{-8}$), both of which were implicated in a recent meta-analysis of T2D in south Asians¹⁰. Neither has previously been reported in European studies, and both retain genome-wide significance after removing PROMIS data from the meta-analysis (*HMG20A* $P = 1.9 \times 10^{-9}$; *GRB14* $P = 5.8 \times 10^{-9}$). The lead SNPs from both meta-analyses are in strong linkage disequilibrium (LD) (*HMG20A* $r^2 = 0.89$ and *GRB14* $r^2 = 0.77$ in CEU) and likely represent the same association signals. At the previously unreported loci, we observed nominal evidence of association ($P < 0.05$) in the south Asian¹⁰ and recent east Asian¹¹ meta-analyses for the lead SNPs at *MC4R* and *ZMIZ1* (Supplementary Table 3), with consistent directions of effect across all three ancestry groups.

A full list of authors and affiliations appears at the end of the paper.

Received 23 January; accepted 11 July; published online 12 August 2012; doi:10.1038/ng.2383



Table 1 Newly identified T2D susceptibility loci achieving genome-wide significance (combined meta-analysis $P < 5 \times 10^{-8}$) in populations of European descent

SNP	Chr.	Position (Build 36)	Alleles ^a			Nearby gene	Stage 1 meta-analysis: up to 12,171 cases and 56,862 controls		Stage 2 meta-analysis: up to 22,669 cases and 58,119 controls		Combined meta-analysis: up to 34,840 cases and 114,981 controls	
			Risk	Other	RAF ^b		OR (95% CI)	<i>P</i> value	OR (95% CI)	<i>P</i> value	OR (95% CI)	<i>P</i> value
New loci not previously reported in any population												
rs12571751	10	80612637	A	G	0.52	<i>ZMIZ1</i>	1.09 (1.06–1.13)	7.0 × 10 ^{−7}	1.07 (1.04–1.10)	1.5 × 10 ^{−6}	1.08 (1.05–1.10)	1.0 × 10 ^{−10}
rs516946	8	41638405	C	T	0.76	<i>ANK1</i>	1.10 (1.06–1.15)	2.1 × 10 ^{−6}	1.08 (1.05–1.12)	1.1 × 10 ^{−6}	1.09 (1.06–1.12)	2.5 × 10 ^{−10}
rs10842994	12	27856417	C	T	0.80	<i>KLHDC5</i>	1.09 (1.04–1.13)	3.0 × 10 ^{−4}	1.10 (1.07–1.14)	2.8 × 10 ^{−8}	1.10 (1.06–1.13)	6.1 × 10 ^{−10}
rs2796441	9	83498768	G	A	0.57	<i>TLE1</i>	1.07 (1.03–1.12)	4.8 × 10 ^{−4}	1.07 (1.04–1.10)	3.3 × 10 ^{−7}	1.07 (1.05–1.10)	5.4 × 10 ^{−9}
rs459193	5	55842508	G	A	0.70	<i>ANKRD55</i>	1.05 (1.01–1.10)	2.7 × 10 ^{−2}	1.10 (1.06–1.13)	2.0 × 10 ^{−9}	1.08 (1.05–1.11)	6.0 × 10 ^{−9}
rs10401969	19	19268718	C	T	0.08	<i>CILP2</i>	1.13 (1.05–1.21)	9.2 × 10 ^{−4}	1.14 (1.08–1.20)	2.0 × 10 ^{−7}	1.13 (1.09–1.18)	7.0 × 10 ^{−9}
rs12970134	18	56035730	A	G	0.27	<i>MC4R</i>	1.08 (1.03–1.12)	2.3 × 10 ^{−4}	1.08 (1.05–1.11)	2.0 × 10 ^{−6}	1.08 (1.05–1.11)	1.2 × 10 ^{−8}
rs7202877	16	73804746	T	G	0.89	<i>BCAR1</i>	1.15 (1.07–1.23)	5.0 × 10 ^{−5}	1.10 (1.05–1.15)	1.9 × 10 ^{−5}	1.12 (1.07–1.16)	3.5 × 10 ^{−8}
Loci not previously reported in populations of European descent												
rs7177055	15	75619817	A	G	0.68	<i>HMG20A</i>	1.08 (1.04–1.12)	1.2 × 10 ^{−4}	1.08 (1.05–1.11)	8.8 × 10 ^{−7}	1.08 (1.05–1.10)	4.6 × 10 ^{−9}
rs13389219	2	165237122	C	T	0.60	<i>GRB14</i>	1.05 (1.01–1.09)	1.3 × 10 ^{−2}	1.09 (1.06–1.12)	9.5 × 10 ^{−9}	1.07 (1.05–1.10)	1.0 × 10 ^{−8}

Chr., chromosome.

^aAlleles are aligned to the forward strand of NCBI Build 36. ^bWeighted mean frequency of T2D risk allele across stage 2 studies.

Several of these signals map to loci previously implicated in T2D-related metabolic traits (Supplementary Table 4). The lead SNP at *MC4R* is in strong LD with variants associated with body mass index (BMI)^{14,15} (CEU $r^2 = 0.80$) and triglyceride concentration¹⁶ (CEU $r^2 = 0.84$) and is associated with waist circumference and insulin resistance¹⁷. As with *FTO*, the effect on T2D at *MC4R* is probably secondary to the association with BMI. The lead SNP at *GRB14* is highly correlated with variants associated with waist-hip ratio (WHR)¹⁸ and high-density lipoprotein (HDL) cholesterol¹⁶ (CEU $r^2 = 0.93$). At *CILP2*, the lead SNP for T2D is also associated with triglyceride, low-density lipoprotein (LDL) and total cholesterol concentrations¹⁶. In contrast, the previously reported association signals for hemoglobin A1C (HbA_{1C}) concentrations¹⁹ near *ANK1* are both independent (CEU $r^2 < 0.01$) of the lead T2D-associated SNP from our meta-analysis. Given the role of rare *ANK1* mutations in hereditary anemias, the HbA_{1C} associations at this locus were assumed to be driven by abnormal erythrocyte development and/or function. However, our newly discovered independent association with T2D (in cohorts where HbA_{1C} was not used for diagnosis) suggests that variation at this locus also has direct effects on glucose homeostasis.

Insights into the genetic architecture of T2D

The associated lead variants at the eight newly identified loci were common (stage 2 RAFs 0.08–0.89) and had modest effects on T2D susceptibility (allelic odds ratios (ORs) 1.07–1.14). Under a multiplicative model within and between variants, the sibling relative risk attributable to lead SNPs rose from $\lambda_s = 1.093$ at the 55 previously described autosomal T2D loci represented on Metabochip (*DUSP9* on chromosome X is not captured) to $\lambda_s = 1.104$ after inclusion of the 8 newly discovered loci (Supplementary Table 5). Assuming a population prevalence for T2D of 8%, these 63 newly discovered and established autosomal loci together account for 5.7% of variance in disease susceptibility, as calculated by transforming dichotomous disease risk onto a continuous liability scale²⁰ (Online Methods).

To determine the extent to which additional common variant associations contribute to the overall variance explained, we compared directional consistency in allelic effects between the two stages of the meta-analysis. The distribution of Z scores from stage 2, aligned to the risk allele from stage 1, was evaluated at a subset of 3,412 independent

(CEU $r^2 < 0.05$) T2D replication variants that excludes lead SNPs and possible proxies (CEU $r^2 \geq 0.1$) at the 63 newly discovered and established loci represented on Metabochip (Fig. 1). Relative to the expected distribution of stage 2 Z scores under the null hypothesis of no association, there is a clear shift in the observed distribution, corresponding to closer agreement in the direction of allelic effect than expected by chance: 2,172 (69.1%) of the 3,412 SNPs are concordant (binomial test $P = 2.0 \times 10^{-104}$). For comparison, we examined T2D association patterns in 2,707 independent replication SNPs for QT interval, the trait showing the weakest correlation with T2D susceptibility among those contributing to Metabochip, and found far less directional consistency (54.4%, binomial test $P = 3.3 \times 10^{-6}$). This modest enrichment most likely reflects weak overlap of risk alleles between the two traits, as exclusion of SNPs mapping within 300 kb of directionally consistent T2D replication variants reduced this excess (52.5%, binomial test $P = 0.060$).

The observed distribution of Z scores can be considered a mixture of (i) the ‘null distribution’ of SNPs having no effect on T2D and (ii) the ‘alternative distribution’ of T2D-associated SNPs (Online Methods).





Figure 1 Distribution of Z scores from the stage 2 meta-analysis, aligned to the risk allele from stage 1. Z scores were calculated at a subset of 3,412 independent T2D replication SNPs (CEU $r^2 < 0.05$), excluding the 63 established and newly discovered autosomal susceptibility loci represented on Metabochip. The Z-score distribution is a mixture of the null distribution of SNPs having no effect on T2D (blue curve) and the alternative distribution of SNPs associated with the disease (red curve).

Figure 2 Regional plots of T2D susceptibility loci with evidence of multiple association signals. Each circle represents a MetaboChip SNP passing quality control in our combined meta-analysis plotted with its association P value (on a $-\log_{10}$ scale) as a function of genomic position (NCBI Build 36). For each locus, the lead SNP is represented by a purple diamond. The color of all other SNPs indicates LD with the lead SNP (estimated by CEU r^2 from 1000 Genomes Project data, June 2010 release). Recombination rates are estimated from International HapMap Project data, and gene annotations are taken from the UCSC Genome Browser.



We estimated the features of this alternative distribution and noted that addition of this class of SNPs significantly improved the fit to the observed Z scores over the null model. Using simulations, based on parameter estimates from this mixture model, we estimated that 488 (95% confidence interval (CI) 456–521) of the independent replication SNPs, in addition to the 63 newly discovered and established loci, are associated with T2D susceptibility. For comparison, we undertook false discovery rate (FDR) analysis of the 64,646 SNPs on the MetaboChip selected for replication of any trait, using P values from the combined meta-analysis (Online Methods). We observed broad agreement between combined meta-analysis P values, FDR Q values and the posterior probabilities of alternative distribution membership from the mixture model (**Supplementary Fig. 4**).

We were concerned that these additional, weaker association signals might reflect subtle stratification effects not eliminated by genomic control correction. However, using diverse European populations from the 1000 Genomes Project¹³ (Online Methods), we found no evidence that directionally consistent T2D replication SNPs differed from other MetaboChip replication SNPs with respect to F_{ST} ($P = 0.88$), a measure of relatedness between populations.

As expected, the estimated allelic ORs of the 488 SNPs were modest (1.01–1.11 in stage 2), and larger samples would be required to establish association at genome-wide significance. For example, by simulating an additional 100,000 T2D cases and 100,000 controls and adding these individuals to the combined meta-analysis, we calculated that only ~37% of the 488 replication SNPs in the alternative distribution would achieve this threshold. We estimate that these variants jointly account for $\lambda_S = 1.088$ (95% CI 1.083–1.094), increasing the overall liability-scale variance explained to 10.7% (10.4–11.0%).

Additional sources of variation contributing to susceptibility

These estimates likely set a lower bound to the overall liability-scale variance attributable to common SNPs. The mixture model does not take into account loci not represented by MetaboChip T2D replication SNPs, due to shortcomings in array design or manufacture or because the associations signal in DIAGRAMv3 were too weak to merit inclusion of the corresponding SNPs on the array. Indeed, the latter applied to two of the newly identified susceptibility loci, *ANKRD55* and *GRB14*, which were nominated for inclusion on MetaboChip because of nominal associations with WHR (*ANKRD55* and *GRB14*), blood pressure (*ANKRD55*) and plasma lipid concentrations (*GRB14*), rather than T2D.

To estimate the contribution to the variance explained by common variants across the genome, we undertook polygenic mixed linear modeling analyses using genome-wide complex trait analysis (GCTA)^{21,22} in two DIAGRAMv3 GWAS data sets: Diabetes Genetics Initiative (DGI; 1,022 cases, 1,075 controls) and the Wellcome Trust Case Control Consortium (WTCCC; 1,924 cases, 2,938 controls). The estimated liability-scale variance explained by the full set of GWAS SNPs was consistent between the two studies: 62.6% for DGI (95% CI 38.1–87.1%) and 63.9% for WTCCC (95% CI 52.1–75.8%). These results are similar to those obtained from a complementary method integrating polygenic risk score analysis and approximate Bayesian computation²³ applied to the DIAGRAMv2 meta-analysis⁴, which estimated that ~49% of liability-scale variance was explained by common variants across the genome. These data indicate that a substantial proportion of the variation in T2D risk is captured by common variant association signals that, individually, lie beyond unequivocal detection in single-SNP analyses.

The DIAGRAMv2 meta-analysis⁴ provided some evidence for loci harboring multiple independent association signals. To understand the extent to which additional variance might be attributable to multiple variants at established and newly discovered loci, we extended these analyses, focusing on the detection of independent (CEU $r^2 < 0.05$) association signals that lie outside the recombination interval containing the lead SNP (**Supplementary Table 2**). We detected two loci at which multiple independent association signals attained genome-wide significance: *KCNQ1* (rs163184, $P = 1.2 \times 10^{-11}$; rs231361, $P = 1.2 \times 10^{-9}$; CEU $r^2 = 0.01$) and *CDKN2A-CDKN2B* (rs10811661, $P = 3.7 \times 10^{-27}$; rs944801, $P = 2.4 \times 10^{-9}$; CEU $r^2 = 0.01$) (**Fig. 2**). Both signals at *KCNQ1* have previously been reported in east Asian and European populations^{4,24}. However, the secondary signal at *CDKN2A-CDKN2B*, which maps to the non-coding *CDKN2B-AS1* (*ANRIL*) transcript, has not previously been implicated in T2D susceptibility. This signal

Table 2 T2D susceptibility loci with sex-differentiated evidence of association

Table 2. Sex-differentiating loci with sex-differentiated evidence of association												
SNP	Chr.	Position (Build 36)	Alleles ^a			Nearby gene	Male meta-analysis: up to 20,219 cases and 54,604 controls		Female meta-analysis: up to 14,621 cases and 60,377 controls		Sex-differentiated meta-analysis: up to 34,840 cases and 114,981 controls	
			Risk	Other	RAF ^b		OR (95% CI)	P value	OR (95% CI)	P value	Association P value	Heterogeneity P value
New loci identified through sex-differentiated meta-analysis achieving genome-wide significance ($P < 5 \times 10^{-8}$)												
rs11063069	12	4244634	G	A	0.21	<i>CCND2</i>	1.12 (1.08–1.16)	1.1×10^{-9}	1.04 (1.00–1.09)	3.6×10^{-2}	9.8×10^{-10}	1.3×10^{-2}
rs8108269	19	50850353	G	T	0.31	<i>GIPR</i>	1.05 (1.02–1.08)	3.7×10^{-3}	1.10 (1.06–1.14)	2.2×10^{-7}	2.1×10^{-8}	5.7×10^{-2}
Other loci with nominally significant evidence ($P < 0.05$) of heterogeneity in allelic ORs between the sexes												
rs163184	11	2803645	G	T	0.50	<i>KCNQ1</i>	1.12 (1.09–1.16)	8.5×10^{-15}	1.05 (1.01–1.08)	7.8×10^{-3}	2.4×10^{-15}	1.3×10^{-3}
rs17168486	7	14864807	T	C	0.19	<i>DGKB</i>	1.15 (1.11–1.19)	6.5×10^{-13}	1.06 (1.02–1.11)	5.2×10^{-3}	1.2×10^{-13}	6.8×10^{-3}
rs3923113	2	165210095	A	C	0.63	<i>GRB14</i>	1.05 (1.01–1.08)	4.9×10^{-3}	1.11 (1.08–1.15)	1.8×10^{-9}	2.6×10^{-10}	8.0×10^{-3}
rs243088	2	60422249	T	A	0.45	<i>BCL11A</i>	1.10 (1.06–1.13)	6.5×10^{-10}	1.04 (1.00–1.07)	2.8×10^{-2}	4.7×10^{-10}	1.2×10^{-2}

Chr, chromosome.

^aAlleles are aligned to the forward strand of NCBI Build 36. ^bWeighted mean frequency of T2D risk allele across stage 2 studies.

is independent of the previously reported haplotype effect at the primary T2D signal at this locus, which is itself likely a result of the phase relationships between two clades of partially correlated variants^{25,26}. We also observed putative independent associations ($P < 1 \times 10^{-5}$) at *DGKB* (rs17168486, $P = 5.9 \times 10^{-11}$; rs6960043, $P = 3.4 \times 10^{-7}$; CEU $r^2 = 0.01$) and *MC4R* (rs12970134, $P = 1.2 \times 10^{-8}$; rs11873305, $P = 3.8 \times 10^{-7}$; CEU $r^2 = 0.02$). These results suggest that multiple independent association signals are widespread at T2D susceptibility loci. Imputation up to the more densely typed reference panels emerging from the 1000 Genomes Project¹³ and recently developed approaches that support approximate conditional analyses using meta-analysis summary-level data²⁷ will be important tools for documenting the full extent of such effects, especially where the variants map to the same recombination interval.

It has been argued that common variant association signals will often reflect unobserved causal alleles of lower frequency and greater effect size²⁸. The fine-mapping content of Metabochip allowed us to seek empirical evidence to support this synthetic association hypothesis. We estimate, using 1000 Genomes Project data¹³ applied to HapMap CEU samples, that the array captures (CEU $r^2 \geq 0.8$) 89.6% of common SNPs (minor allele frequency (MAF) $\geq 5\%$) and 60.0% of low-frequency variants ($1\% \leq \text{MAF} < 5\%$) across Metabochip fine-mapping regions¹². This represents a substantial improvement over HapMap^{29,30}, which, across the same regions, captures 76.8% and 32.4% of common and low-frequency variants, respectively.

Across 36 fine-mapping regions on Metabochip that contain T2D susceptibility loci (including 27 explicitly chosen by DIAGRAM), we compared the characteristics of previously reported lead SNPs (defined by GWAS and HapMap imputation) and those emerging from the stage 2 Metabochip meta-analysis. We restricted these comparisons to stage 2 to avoid penalizing low-frequency variants not typed or well imputed in stage 1. The GWAS and Metabochip lead SNPs were the same or highly correlated (CEU $r^2 > 0.8$) at 20 loci (15 with CEU $r^2 > 0.95$) (Supplementary Table 6). The low LD between GWAS and Metabochip lead SNPs at *DGKB* and *KCNQ1* (both CEU $r^2 = 0.00$) arises because of a switch of the lead SNP from one independent association signal to the other at these loci (Fig. 2). For the remaining 14 loci, there was only modest LD between the previously reported GWAS- and Metabochip-defined lead SNPs (CEU r^2 between 0.06 and 0.77). However, at only two loci did the lead SNP after Metabochip fine mapping have substantially lower MAF and higher OR than the previously reported GWAS lead SNP: *PROX1* (rs17712208: MAF = 0.03,

OR = 1.20; rs340874: MAF = 0.48, OR = 1.06) and *KLF14* (7-130116320: MAF = 0.02, OR = 1.10; rs972283: MAF = 0.48, OR = 1.01). Because coverage across Metabochip fine-mapping regions is incomplete, we cannot unequivocally exclude the presence of causal low-frequency alleles at any single locus. However, the paucity of low-frequency candidate alleles across 36 loci suggests that most causal variants at these loci are common. A contribution of even rarer causal alleles (too rare to be represented on Metabochip) is also unlikely because the substantial effect sizes required to drive common variant association signals are inconsistent with the modest familial aggregation of T2D²³. This interpretation, favoring common causal alleles, is in agreement with the observed consistency of T2D risk variant associations across major ancestry groups³¹.

Sex-differentiated analyses

We performed sex-differentiated meta-analysis³² (Online Methods and Supplementary Figs. 5 and 6) to test for association of each SNP with T2D, allowing for heterogeneity in allelic effects between males (20,219 cases, 54,604 controls) and females (14,621 cases, 60,377 controls), thereby identifying 2 additional loci achieving genome-wide significance (Table 2 and Supplementary Table 7). The association signal mapping near *CCND2* is most significant in males (male $P = 1.1 \times 10^{-9}$, female $P = 0.036$; heterogeneity $P = 0.013$), whereas that upstream of *GIPR* is most significant in females (female $P = 2.2 \times 10^{-7}$, male $P = 0.0037$; heterogeneity $P = 0.057$) (Supplementary Fig. 7). The lead sex-differentiated SNP in *GIPR* is only weakly correlated with previously reported associations with BMI¹⁵ (CEU $r^2 = 0.06$) and with two-hour glucose levels³³ (CEU $r^2 = 0.07$) (Supplementary Table 4).

The sex-differentiated analyses also revealed nominal evidence of heterogeneity ($P < 0.05$) at four established T2D susceptibility loci (Table 2 and Supplementary Tables 7 and 8): *KCNQ1* ($P = 0.0013$), *DGKB* ($P = 0.0068$) and *BCL11A* ($P = 0.012$) were most significantly associated in males, and *GRB14* ($P = 0.0080$) was most significantly associated in females. The sex-differentiated association at *GRB14* is consistent with the female-specific effect on WHR observed at this locus¹⁸. As *KCNQ1* and *DGKB* showed multiple independent associations in the sex-combined meta-analysis, we investigated whether sex differences in allelic effects were consistent across these signals (Supplementary Fig. 8). This seemed to be true for *DGKB* (rs17168486: male $P = 6.5 \times 10^{-13}$, female $P = 0.0052$; rs6960043: male $P = 7.9 \times 10^{-7}$, female $P = 0.015$) but not for *KCNQ1* (rs163184: male $P = 8.5 \times 10^{-15}$, female $P = 7.8 \times 10^{-3}$; rs231361: male $P = 2.9 \times 10^{-6}$, female $P = 2.9 \times 10^{-6}$).

Understanding the biology of T2D susceptibility loci

For most T2D susceptibility loci, the underlying causal variants and the genes through which they act are yet to be identified, and the pathophysiological processes mediating disease risk remain unclear. We applied a variety of approaches to the newly discovered and established T2D susceptibility loci and, in some cases, to putative T2D loci with more modest evidence of association to identify mechanisms involved in disease pathogenesis.

Physiological analyses

As noted, lead SNPs at several newly identified loci are in strong LD with variants associated with other T2D-related metabolic traits. To gain a more complete understanding of patterns of trait overlap, we first assessed the effect of T2D risk alleles on glycemic traits in meta-analyses of studies conducted in individuals of European descent from the Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) Investigators (Online Methods). Associations with fasting glucose concentration were analyzed for up to 133,010 non-diabetic individuals with GWAS and/or MetaboChip data³⁴. In addition to the nine loci previously reported (*MTNR1B*, *DGKB*, *ADCY5*, *PROX1*, *GCK*, *GCKR*, *TCF7L2*, *SLC30A8* and *C2CD4A*)^{4,5}, four more T2D association signals reached genome-wide significance for fasting glucose: *CDKN2A-CDKN2B* ($P = 5.7 \times 10^{-18}$), *ARAP1* ($P = 1.2 \times 10^{-10}$), *IGF2BP2* ($P = 1.8 \times 10^{-8}$) and *CDKAL1* ($P = 2.0 \times 10^{-8}$) (Supplementary Table 9). The *ZBED3* locus also attained genome-wide significance with fasting glucose concentration after adjustment for BMI ($P = 1.2 \times 10^{-8}$). In contrast, lead T2D-associated SNPs at 27 of the newly discovered and established loci showed no evidence of association with fasting glucose ($P > 0.05$), despite sample sizes ranging from 38,424 to 132,999 individuals (Supplementary Fig. 9 and Supplementary Table 10). Lead T2D-associated SNPs at the remaining 24 loci were nominally associated with fasting glucose concentrations ($P < 0.05$), all with directionally consistent effects. These data extend previous reports indicating that the genetic landscapes of pathological and physiological variation in glycemia are only partially overlapping and are consistent with reciprocal analyses reported in the accompanying paper from the MAGIC Investigators³⁴.

Second, we extended our previous analysis⁴ of the physiological consequences of T2D risk alleles to include the newly identified loci. We used the published MAGIC meta-analysis (up to 37,037 non-diabetic individuals) of homeostatic model of assessment (HOMA) indices of β -cell function and insulin sensitivity⁵, as these traits were not analyzed in the enlarged MetaboChip study³⁴. The risk allele at *ANK1* has features (nominally significant reduction in HOMA-B) indicating a primary effect on β -cell function, whereas those at *GRB14* and *AKNRD55* are characteristic of loci acting primarily through insulin resistance (increased HOMA-IR) (Supplementary Fig. 10 and Supplementary Table 10). The results for *GRB14* are consistent with its broad impact on insulin resistance-related traits, whereas, at *AKNRD55*, these analyses point to *MAP3K1*, encoding a MEK kinase that is a key component of the insulin signaling pathway, as the standout local candidate.

Next, we examined the effect of T2D risk alleles on anthropometric and lipid traits, using data from the Genetic Investigation of Anthropometric Traits (GIANT) Consortium (up to 119,600 individuals, after excluding data from T2D case series)¹⁵ and the Global Lipids Genetics Consortium (up to 100,184 individuals)¹⁶ (Online Methods and Supplementary Tables 11 and 12). The only lead SNP to show convincing evidence of association ($P < 1 \times 10^{-5}$) with adiposity was at *MC4R*. The lead SNPs at *MC4R* and *GRB14* showed the same pattern of lipid associations ($P < 1 \times 10^{-5}$), featuring lower HDL and higher triglyceride concentrations. In contrast, the lipid associations at *CILP2* and *GIPR* ran counter to expected epidemiological correlations: T2D risk

alleles were associated with lower triglyceride concentrations at both loci and, at *CILP2*, with lower LDL and total cholesterol concentrations.

Finally, we noticed that the lead T2D-associated SNP at the *BCAR1* locus is also associated at genome-wide significance with type 1 diabetes (T1D)³⁵, although risk is conferred by the opposite allele than for T2D. Across 37 T1D susceptibility loci (Supplementary Fig. 11), we observed nominal evidence ($P < 0.05$) of association to T2D at 6. For three of these (*BCAR1*, *GLIS3* and *RAD51L1*), the T1D risk allele was protective for T2D, whereas, at the others (*C6orf173*, *COBL* and *C10orf59*), the effects were coincident. These data indicate that rates of diagnostic misclassification among T2D cases in our study are low and also highlight noteworthy points of overlap in the processes involved in risk of and protection from these two major forms of diabetes.

Mapping potential causal transcripts and variants

The T2D association signals emerging from the present meta-analysis map to regions containing many transcripts and potential functional variants. To identify promising regional transcripts, we examined expression quantitative trait locus (eQTL) data from a variety of tissues (Online Methods and Supplementary Note). At six of the newly discovered loci, the lead T2D-associated SNP showed strong *cis*-eQTL associations and was highly correlated (CEU $r^2 > 0.8$) with the lead *cis*-eQTL SNP (Supplementary Table 13). These coincident eQTLs implicate *GRB14* (omental fat), *ANK1* (omental and subcutaneous fat, liver and prefrontal cortex), *KLHDC5* (blood, T cells and CD4⁺ lymphocytes), *BCAR1* (blood), *ATP13A1* (at the *CILP2* locus; blood and monocytes), *HMG20A* (liver) and *LINGO1* (also at the *HMG20A* locus; adipose tissue). For those loci (*GRB14*, *ANK1* and *BCAR1*) for which individual-level expression data for the appropriate tissues were available³⁶, we confirmed signal coincidence by conditional analyses (Online Methods and Supplementary Table 14).


We used 1000 Genomes Project data¹³ to search for nonsynonymous variants in strong LD (CEU $r^2 > 0.8$) with lead SNPs at the newly discovered loci (Online Methods). The only candidate allele uncovered was a nonsynonymous variant in exon 6 of *TM6SF2* (19-19379549; CEU $r^2 = 0.98$ with rs10401969) at the *CILP2* locus. This change is predicted by SIFT³⁷ to have no appreciable effect on protein function.

Pathway and protein-protein interaction analyses

To extend previous efforts to define pathways and networks involved in T2D pathogenesis⁴, we combined meta-analysis data with protein-protein interactions (PPIs), semantic relationships within the published literature and annotated pathways (Fig. 3). For these analyses, we generated a primary list of 77 transcripts mapping nearest to lead SNPs at T2D susceptibility loci or implicated in monogenic diabetes³⁸ (Online Methods and Supplementary Table 15).

Using a refined database of high-confidence PPIs^{39,40}, we constructed a network of 314 proteins from these 77 transcripts using DAPPLE⁴¹. We detected an excess of physical interactions in the network, both direct (between the associated transcripts themselves; $P < 1 \times 10^{-4}$) and indirect (via 237 shared interactors not on the list of associated transcripts; $P = 0.0070$). There was no evidence that this set of shared interactors was enriched for T2D-associated variants. Some interactions, such as those between the potassium channel-encoding genes *KCNJ11* and *ABCC8*, are expected, whereas other subnetworks are of greater novelty. For example, the transcriptional co-activator protein *CREBBP*, implicated in the coupling of chromatin remodeling to transcription factor recognition, does not map to any T2D susceptibility locus. However, it is the most connected gene for protein-level interactions ($P < 0.005$) in the PPI network, interacting with nine primary transcripts, eight implicated in monogenic diabetes

Figure 3 Functional analyses. (a,b) PPI subnetwork for CREBBP (a) and adipocytokine (b) interactions. All direct interactions and common interactors between direct connections were extracted from the larger network of 314 proteins defined in DAPPLE network analysis. Genes in the network are represented as circles (nodes), colored according to the statistical relationship with T2D: gray, common interactors between GWAS-identified or monogenic loci; blue, monogenic loci only; red, GWAS-identified loci only; green, loci with GWAS association and implicated by monogenic forms of diabetes. Each interaction defined in the inWEB network is depicted by a line (edge) between nodes. (c) GRAIL circle plot of locus connectivity. Each locus is plotted in a circle, where significant connections ($P < 0.05$) based on PubMed abstracts are drawn spanning the circle. Conservatively, we treated all monogenic loci (region 142) as a single locus by which connectivity was assessed. The strongest connections ($P < 0.001$) are colored in bright red. (d) GSEA of associations in the adipocytokine signaling pathway. Black bars represent the stage 1 meta-analysis P values of 63 autosomal genes in the adipocytokine signaling pathways (KEGG). Top, density plot of the black bars (red line). The replicating genes in the leading edge of the GSEA are listed. Stage 2 modified GSEA $P = 1.6 \times 10^{-4}$ was calculated on the basis of both the primary and secondary transcripts using the LD locus definition.



or mapping to established T2D susceptibility loci (*HNF1A*, *HNF1B*, *HNF4A*, *PLAGL1*, *TCF7L2*, *PPARG*, *PROX1* and *NOTCH2*) and one from a locus with a strong but not genome-wide significant association (*ETS1*, lead SNP rs7931302, $P = 3.8 \times 10^{-7}$). Other shared interactors identified through these analyses included *SERTAD1*, *FOXO1*, *PPARGC1A*, *GRB10* and *MAFA*. Several of these have roles in the transcriptional regulation of diabetes-relevant tissues, and some also interact with *CREBBP*. We used a predefined set of 1,814 genes encoding 'DNA-binding proteins' (Online Methods) to show that (i) T2D signals are highly enriched for transcription factors (21 of 71 primary transcripts listed within the HGNC catalog, compared to 1,793 of 19,162, $P = 2.3 \times 10^{-6}$) and (ii) transcription factors within T2D-associated loci are enriched for interaction with *CREBBP* (taking the 1,164 listed in the protein interaction database, 9 of 21 compared with 127 of 1,143, $P = 2.7 \times 10^{-4}$). These data suggest that modulation of CREBBP-binding transcription factors has an important role in T2D susceptibility.

The same set of 77 primary transcripts showed modest evidence of excess connectivity ($P = 0.020$ by permutation) using text-mining approaches⁴² (Online Methods). When we used this set of 77 genes as a seed to query a list of 77 secondary transcripts (nearest to lead SNPs with posterior probability of T2D association of >75% from the mixture model) (Supplementary Table 15), we found significant connections ($P < 0.001$) between the primary associated transcripts and four other genes: *LEPR* (leptin obesity pathways), *MYC* (cell cycle pathway), *GATA6* (pancreas development pathway) and *DLL4* (Notch signaling target).

We also tested for enrichment of GWAS-associated transcripts in pathway data. To retain power, we focused on 16 biological

hypotheses chosen for assumed relevance to T2D pathogenesis^{4,43–45} (Supplementary Note). We used a two-step modified gene-set enrichment analysis (GSEA) approach applied sequentially to stage 1 (using MAGENTA⁴⁶) and stage 2 meta-analyses (Online Methods and Supplementary Table 16). Of the 16 biological hypotheses tested, 2 showed reproducible enrichment of T2D associations. The strongest enrichment was observed for a broader set of primary and secondary transcripts mapping to T2D-associated loci in the adipocytokine signaling pathway (MAGENTA $P = 6.2 \times 10^{-5}$; modified GSEA $P = 1.6 \times 10^{-4}$). This gene set includes the adiponectin, leptin and tumor necrosis factor (TNF)- α signaling pathways previously implicated in the development of insulin resistance⁴⁷ but for which genome-wide significant common variant associations with T2D susceptibility had not been previously reported. This analysis highlighted eight genes in this pathway most likely to be causal for T2D susceptibility: *IRS1*, *LEPR*, *RELA*, *RXRG*, *ACSL1*, *NFKB1*, *CAMKK1* and a monogenic diabetes gene, *AKT2*. Members of this pathway were also strongly represented (17 out of 314) in the DAPPLE PPI network ($P = 7.5 \times 10^{-14}$). Modest but robust enrichment was also observed for genes influencing cell cycle, in particular, regulators of the G1 phase during mitosis (MAGENTA $P = 2.0 \times 10^{-4}$; modified GSEA $P = 3.0 \times 10^{-3}$). The majority of genes driving these cell cycle enrichments were cyclin-dependent kinase (CDK) inhibitors (*CDKN2A-CDKN2B*, *CDKN1C* and *CDKN2C*) and cyclins that activate CDKs (*CCNE2*, *CCND2* and *CCNA2*). Many of these regulate *CDK4* or *CDK6*, which are known to have a role in pancreatic β -cell proliferation^{48,49}. We saw no evidence of enrichment for other processes implicated in T2D pathogenesis, including amyloid formation, endoplasmic reticulum stress and insulin signaling.

DISCUSSION

We have expanded T2D association analysis to almost 150,000 individuals. In so doing, we have added another ten loci to the list of confirmed common variant signals: for several of these, we have identified strong positional candidates on the basis of expression data and known biology. The data support the view that much of the overall variance in T2D susceptibility can be attributed to the impact of a large number of common causal variants, most of very modest effect. Although such a model poses challenges for accumulating genome-wide significant evidence of association at a specific variant, it does suggest that genetic profiling of the entirety of sequence variation has the potential to provide useful risk stratification for T2D.

If common causal alleles explain a substantial component of T2D susceptibility, the contribution of rare and low-frequency risk variants may be less than is often assumed: resequencing studies will soon provide empirical data to address this hypothesis. In particular, it will be important to determine whether, as the number of susceptibility loci increases, there is evidence that the pathophysiological mechanisms implicated by human genetics coalesce around a limited set of core pathways and networks. Our data suggest that this may be the case, with a variety of analytical approaches pointing to cell cycle regulation, adipocytokine signaling and CREBBP-related transcription factor activity as key processes involved in T2D pathogenesis.

METHODS

Methods and any associated references are available in the online version of the paper.

Note: Supplementary information is available in the online version of the paper.

ACKNOWLEDGMENTS

Funding for this study was provided by the Academy of Finland (77299, 102318, 110413, 118065, 123885, 124243, 129680, 129293, 129494, 136895, 139635, 141005, 213506 and 251217); Agence Nationale de la Recherche (France); the American Diabetes Association (7-08-MN-OK); Association Française des Diabétiques; Association de Langue Française pour l'Etude du Diabète et des Maladies Métaboliques (France); Association Diabète Risque Vasculaire (France); British Diabetic Association (BDA) Research (UK); the British Heart Foundation (RG/98002 and RG2008/08); Cancer Research UK; the Central Norway Health Authority; the Central Finland Hospital District; the Center for Inherited Disease Research (CIDR) (USA); the Chief Scientist Office, Scotland (CZB/4/672); the City of Kuopio (Finland); the City of Leutkirch (Germany); the Department of Health (UK); Deutsche Forschungsgemeinschaft (ER1 55/6-2); Diabetes UK; the Doris Duke Charitable Foundation (USA); the Estonian government (SF018014250); the European Commission: ENGAGE (HEALTH-F4-2007- 201413), EXGENESIS (LSHM-CT-2004-005272), 245536, QLGI-CT-2002-00896 and 2004310; the European Commission (Marie Curie: FP7-PEOPLE-2010-IEF); the European Regional Development Fund; the Faculty of Medicine at the Norwegian University of Science and Technology; the Finnish Diabetes Association; the Finnish Diabetes Research Foundation; the Finnish Foundation for Cardiovascular Research; the Finnish Heart Association; the Finnish Medical Society; the Folkhälsan Research Foundation (Finland); the Food Standards Agency (UK); the Foundation for Life and Health in Finland; the Federal Ministry of Education and Research (BMBF) (Germany); the Federal Ministry of Health (Germany); the General Secretary of Research and Technology (Greece); the German Center for Diabetes Research (DZD); the German Research Council (GRK 1041); the Great Wine Estates of the Margaret River region of Western Australia; Groupe d'Etude des Maladies Métaboliques et Systémiques (France); Harvard Medical School (USA); the Heinz Nixdorf Foundation (Germany); Helmholtz Zentrum München—Research Center for Environment and Health (Germany); the Helsinki University Central Hospital Research Foundation (Finland); IngaBritt and Arne Lundberg's Research Foundation (Sweden) (grant 359); the Ministry of Health (Ricerca Corrente) (Italy); Karolinska Institutet (Sweden); the Knut and Alice Wallenberg Foundation (Sweden) (KAW 2009.0243); Kuopio University Hospital (Finland); the Municipal Health Care Center and Hospital, Jakobstad, Finland; the Ministry of Social Affairs and Health (Finland); the Ministry of Education and Culture (Finland) (627; 2004–2011); the Ministry of Innovation, Science, Research and Technology of North Rhine-Westphalia (Germany); the Medical

Research Council (UK) (G0000649 and G0601261); an MRC-GSK pilot programme grant (UK); the Munich Center of Health Sciences (MC Health) (Germany); the National Genome Research Network (NGFN) (Germany); the National Heart, Lung, and Blood Institute (NHLBI) (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN268201100009C, HHSN268201100010C, HHSN268201100011C, HHSN268201100012C, R01HL087641, R01HL59367, R01HL086694, N01HC25195 and N02HL64278); the National Human Genome Research Institute (NHGRI) (U01HG004402 and N01HG65403); the US National Institutes of Health (USA) (HHSN268200625226C, UL1RR025005, U01HG004399, 1R21NS064908, 1Z01HG000024, AG028555, AG08724, AG04563, AG10175, AG08861 and CA055075); the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (DK062370, DK058845, DK072193, DK078616, DK080140 and DK073490); the Närpes Health Care Foundation (Finland); the National Health Screening Service of Norway; the National Institute of Health Research (UK); the National Institute for Health and Welfare (Finland); the Nord-Trøndelag County Council (Norway); the Nordic Center of Excellence in Disease Genetics; the Norwegian Institute of Public Health; the Norwegian Research Council; Novo Nordisk Fonden (Denmark); the Ollqvist Foundation (Sweden); the Oxford NIHR Biomedical Research Centre (UK); the Paavo Nurmi Foundation (Finland); the Päivikki and Sakari Sohlberg Foundation (Finland); the Perklén Foundation (Sweden); Pfizer; the Pirkanmaa Hospital District (Finland); Programme National de Recherche sur le Diabète (France); Programme Hospitalier de Recherche Clinique (French Ministry of Health); the Region of Nord-Pas-de-Calais (Contrat de Projets Etat-Région) (France); Research into Ageing (UK); the Robert Dawson Evans Endowment of the Department of Medicine at Boston University School of Medicine and Boston Medical Center; the Royal Swedish Academy of Sciences; Sarstedt AG & Co. (Germany); the Signe and Ane Gyllenberg Foundation (Sweden); the Slottery Machine Association (Finland); the Social Insurance Institution of Finland (4/26/2010); the South Ostrobothnia Hospital District (Finland); the State of Baden-Württemberg, Germany; the Stockholm County Council (560183 and 562183); Stroke Association (UK); the Swedish Research Council (8691, 09533, 2009-1039, Dnr 521-2010-3490, Dnr 521-2007-4037, Dnr 521-2008-2974, Dnr 825-2010-5983 and Dnr 349-2008-6589); the Swedish Cultural Foundation in Finland; the Swedish Diabetes Foundation; the Swedish Heart-Lung Foundation; the Swedish Foundation for Strategic Research; the Swedish Society of Medicine; the Swedish Research Council; the Swedish Research Council for Infrastructures; The Sigrid Juselius Foundation (Finland); the Torsten and Ragnar Söderberg Foundation (Sweden) (MT33/09); University Hospital Essen (Germany); University of Tromsø (Norway); Uppsala University (Sweden); Uppsala University Hospital (Sweden); and the Wellcome Trust (GR072960, 076113, 077016, 081682, 083948, 083270, 084711, 086596, 090367, 090532 and 098051). A more detailed set of acknowledgments is provided in the **Supplementary Note**.

AUTHOR CONTRIBUTIONS

Writing group: A.P.M., B.F.V., T.M.T., T. Ferreira, A.V.S., V. Steinthorsdottir, R.J.S., H.K., H.G., A. Mahajan, I.P., M.B. and M.I.M.

GWAS reanalysis: A.P.M., B.F.V., A.V.S., V. Steinthorsdottir, H.G., I.P., C.D., C.M.L., N.W.R., L.J.S., S.W., S. Raychaudhuri, H. Chen, C.F., C.-T.L., D.R., D.J.C., W.H.L.K., M. Li, M.C.C., P.K., Q.S., R.M.v.D., H.M.S., P.S.C., A. Kong, N.R., G.T., R.B., L.L.B., N.B., G.C., C.J.G., C. Guiducci, C.H., W.R., N.K., G. Sigurdsson, B.T., H. Campbell, C.v.D., A.G.U., A. Hofman, E.S., G.R.A., K.R.O., E.Z., B.B., C.N.A.P., V. Lyssenko, T.T., B.I., D.J.H., L.Q., M.R., J.F.W., F.S.C., K.L.M., R.N.B., J. Tuomilehto, S.C., P. Froguel, T.I., A.D.M., T.M.F., A.T.H., E.B., P.M.N., U.T., L.C.G., K. Stefansson, F.H., J.S.P., J. Dupuis, J.B.M., D.A., M.B. and M.I.M.

Metabochip design: B.F.V., H.M.K., G.R.A., D.A., M.B. and M.I.M.

Metabochip samples: P.A., M.A., R.B., G.C., A.S.F.D., M.D., T. Forsen, B.G., C.H., A.B.H., A. James, A. Jonsson, W.R., J. Kravic, K.L., E.L., S. Männistö, B.M., L.R., J. Samaras, B.S., S. Shah, G. Sigurdsson, A. Silveira, G. Steinbach, B.T., F.V., R.W., D.Z., M.D.T., N.G.F., J.G.E., B.B., C.N.A.P., V. Lyssenko, T.T., B.I., A.R.S., M.R., I.B., J.B., K. Hovingh, J.F.P., J.F.W., R.R., T.A.L., L.L., G.D., I.N., N.L.P., K.-T.K., N.J.W., S.M.K.-K., T.E.S., T.W., E.K.-H., J. Saltevo, M. Laakso, J. Kuusisto, A. Metspalu, F.S.C., K.L.M., R.N.B., J. Tuomilehto, B.O.B., C. Gieger, K. Hveem, S.C., P. Froguel, D.B., E. Tremoli, S.E. Humphries, D.S., J. Danesh, E.L., S. Ripatti, V. Salomaa, R.E., K.-H.J., S. Moebus, A.P., T.I., U.d.F., A. Hamsten, A.D.M., P.J.D., T.M.F., A.T.H., O.M., S. Kathiresan, P.M.N., P.D., U.T., L.C.G., K. Stefansson, D.A., M.B. and M.I.M.

Metabochip genotyping: L.L.B., J.C., A.T.C., S.E., E.E., G.B.G., C.J.G., C. Guiducci, J.H., N.K., K.K., C. Langford, S.L., G.M., T.W.M., M.P., J. Trakalo, W.W., A.-C.S., L.P. and M.M.-N.

Metabochip analysis: A.P.M., B.F.V., T.M.T., T. Ferreira, A.V.S., V. Steinthorsdottir, R.J.S., H.K., H.G., A. Mahajan, I.P., T.E., R.M.F., S. Kanoni, L.K., A. Kumar,

V. Lagou, J.L., C.M.L., M.M.N., S. Pechlivanis, N.W.R., L.J.S., S.W., L.Y., H.M.S., P.S.C., K.F., P. Fontanillas, O.L.H., S.E. Hunt, A.U.J., A. Kong, R.L., J.M., J.R.B.P., C.G.P.P., S. Potter, E.R., N.R., S. Sivapalaratnam, A. Stančáková, K. Stirrups, G.T., E. Tikkanen, A.R.W. and K.G.

Core and additional analyses: A.P.M., B.F.V., T.M.T., T. Ferreira, A.V.S., V. Steinthorsdottir, R.J.S., H.K., H.G., A. Mahajan, I.P., E.J.R., S. Raychaudhuri, A.D.J., A.S.D., R.J.F.L., S.V., V.E., M.B. and M.I.M.

Consortium management: A.P.M., B.F.V., T.M.T., H.G., C. Langenberg, J.C.F., H. Campbell, C.v.D., G.R.A., K.R.O., E.Z., C.N.A.P., V. Lyssenko, A.R.S., I.B., J.F.W., K.L.M., C. Gieger, S.C., P. Froguel, E.I., T.I., A.D.M., T.M.F., A.T.H., U.T., L.C.G., K. Stefansson, F.H., J.S.P., J.B.M., D.A., M.B. and M.I.M.

COMPETING FINANCIAL INTERESTS

The authors declare competing financial interests: details are available in the online version of the paper.

Published online at <http://www.nature.com/dofinder/10.1038/ng.2383>.

Reprints and permissions information is available online at <http://www.nature.com/reprints/index.html>.

1. Stumvoll, M. *et al.* Type 2 diabetes: principles of pathogenesis and therapy. *Lancet* **365**, 1333–1346 (2005).
2. Zeggini, E. *et al.* Meta-analysis of genome-wide association data and large-scale replication identified additional susceptibility loci for type 2 diabetes. *Nat. Genet.* **40**, 638–645 (2008).
3. Kong, A. *et al.* Parental origin of sequence variants associated with complex diseases. *Nature* **462**, 868–874 (2009).
4. Voight, B.F. *et al.* Twelve type 2 diabetes susceptibility loci identified through large scale association analysis. *Nat. Genet.* **42**, 579–589 (2010).
5. Dupuis, J. *et al.* New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. *Nat. Genet.* **42**, 105–116 (2010).
6. Qi, L. *et al.* Genetic variants at 2q24 are associated with susceptibility to type 2 diabetes. *Hum. Mol. Genet.* **19**, 2706–2715 (2010).
7. Tsai, F.-J. A genome-wide association study identifies susceptibility variants for type 2 diabetes in Han Chinese. *PLoS Genet.* **6**, e1000847 (2010).
8. Shu, X.O. *et al.* Identification of new genetic risk variants for type 2 diabetes. *PLoS Genet.* **6**, e1001127 (2010).
9. Yamauchi, T. *et al.* A genome-wide association study in the Japanese population identifies susceptibility loci for type 2 diabetes at *UBE2E2* and *C2CD4A-C2CD4B*. *Nat. Genet.* **42**, 864–868 (2010).
10. Kooner, J.S. *et al.* Genome-wide association study in individuals of South Asian ancestry identifies six new type 2 diabetes susceptibility loci. *Nat. Genet.* **43**, 984–989 (2011).
11. Cho, Y.S. *et al.* Meta-analysis of genome-wide association studies identifies eight new loci for type 2 diabetes in east Asians. *Nat. Genet.* **44**, 67–72 (2012).
12. Voight, B.F. *et al.* The MetaboChip, a custom genotyping array for genetic studies of metabolic, cardiovascular, and anthropometric traits. *PLoS Genet.* **8**, e1002793 (2012).
13. 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. *Nature* **467**, 1061–1073 (2010).
14. Loos, R.J.F. *et al.* Common variants near *MC4R* are associated with fat mass, weight and risk of obesity. *Nat. Genet.* **40**, 768–775 (2008).
15. Speliotes, E.K. *et al.* Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. *Nat. Genet.* **42**, 937–948 (2010).
16. Teslovich, T.M. *et al.* Biological, clinical and population relevance of 95 loci for blood lipids. *Nature* **466**, 707–713 (2010).
17. Chambers, J.C. *et al.* Common genetic variation near *MC4R* is associated with waist circumference and insulin resistance. *Nat. Genet.* **40**, 716–718 (2008).
18. Heid, I.M. *et al.* Meta-analysis identifies 12 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. *Nat. Genet.* **42**, 949–960 (2010).
19. Soranzo, N. *et al.* Common variants at 10 genomic loci influence hemoglobin A_{1c} levels via glycaemic and nonglycaemic pathways. *Diabetes* **59**, 3229–3239 (2010).
20. Wray, N.R. *et al.* The genetic interpretation of area under the ROC curve in genomic profiling. *PLoS Genet.* **6**, e1000864 (2010).
21. Yang, J. *et al.* GCTA: a tool for genome-wide complex trait analysis. *Am. J. Hum. Genet.* **7**, 76–82 (2011).
22. Lee, S.H. *et al.* Estimating missing heritability for disease from genome-wide association studies. *Am. J. Hum. Genet.* **88**, 294–305 (2011).
23. Stahl, E.A. *et al.* Bayesian inference analyses of the polygenic architecture of rheumatoid arthritis. *Nat. Genet.* **44**, 483–489 (2012).
24. Unoki, H. *et al.* SNPs in *KCNQ1* are associated with susceptibility to type 2 diabetes in East Asian and European populations. *Nat. Genet.* **40**, 1098–1102 (2008).
25. Zeggini, E. *et al.* Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. *Science* **316**, 1336–1341 (2007).
26. Shea, J. *et al.* Comparing strategies to fine-map the association of common SNPs at chromosome 9p21 with type 2 diabetes and myocardial infarction. *Nat. Genet.* **43**, 801–805 (2011).
27. Yang, J. *et al.* Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. *Nat. Genet.* **44**, 369–375 (2012).
28. Dickson, S.P. *et al.* Rare variants create synthetic genome-wide associations. *PLoS Biol.* **8**, e1000294 (2010).
29. International HapMap Consortium. A second generation human haplotype map of over 3.1 million SNPs. *Nature* **449**, 851–861 (2007).
30. International HapMap Consortium. Integrating common and rare genetic variation in diverse human populations. *Nature* **467**, 52–58 (2010).
31. Waters, K.M. *et al.* Consistent association of type 2 diabetes risk variants found in Europeans in diverse racial and ethnic groups. *PLoS Genet.* **6**, e1001078 (2010).
32. Magi, R. *et al.* Meta-analysis of sex-specific genome-wide association studies. *Genet. Epidemiol.* **34**, 846–853 (2010).
33. Saxena, R. *et al.* Genetic variation in *GIPR* influences the glucose and insulin responses to an oral glucose challenge. *Nat. Genet.* **42**, 142–148 (2010).
34. Scott, R.A. *et al.* Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. *Nat. Genet.* published online (12 August 2012); doi:10.1038/ng.2385.
35. Barrett, J.C. *et al.* Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. *Nat. Genet.* **41**, 703–707 (2009).
36. Emilsson, V. *et al.* Genetics of gene expression and its effect on disease. *Nature* **452**, 423–428 (2008).
37. Ng, P.C. & Henikoff, S. SIFT: predicting amino acid changes that affect protein function. *Nucleic Acids Res.* **31**, 3812–3814 (2003).
38. Doria, A. *et al.* The emerging genetic architecture of type 2 diabetes. *Cell Metab.* **8**, 186–200 (2008).
39. Lage, K. *et al.* A human phenome-interactome network of protein complexes implicated in genetic disorders. *Nat. Biotechnol.* **25**, 309–316 (2007).
40. Lage, K. *et al.* A large-scale analysis of tissue-specific pathology and gene expression of human disease genes and complexes. *Proc. Natl. Acad. Sci. USA* **105**, 20870–20875 (2008).
41. Rossin, E.J. *et al.* Proteins encoded in genomic regions associated with immune-mediated disease physically interact and suggest underlying biology. *PLoS Genet.* **7**, e1001273 (2011).
42. Raychaudhuri, S. *et al.* Identifying relationships among genomic disease regions: predicting genes at pathogenic SNP associations and rare deletions. *PLoS Genet.* **5**, e1000534 (2009).
43. Muoio, D.M. & Newgard, C.B. Mechanisms of disease: molecular and metabolic mechanisms of insulin resistance and β -cell failure in type 2 diabetes. *Nat. Rev. Mol. Cell Biol.* **9**, 193–205 (2008).
44. Gangwisch, J.E. Epidemiological evidence for the links between sleep, circadian rhythms and metabolism. *Obes. Rev.* **10**, 37–45 (2009).
45. Boucher, B.J. Vitamin D insufficiency and diabetes risks. *Curr. Drug Targets* **12**, 61–87 (2011).
46. Segrè, A.V. *et al.* Common inherited variation in mitochondrial genes is not enriched for associations with type 2 diabetes or related glycemic traits. *PLoS Genet.* **6**, e1001058 (2010).
47. Pittas, A.G. *et al.* Adipocytokines and insulin resistance. *J. Clin. Endocrinol. Metab.* **89**, 447–452 (2004).
48. Rane, S.G. *et al.* Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in β -islet cell hyperplasia. *Nat. Genet.* **22**, 44–52 (1999).
49. Fiaschi-Taesch, N.M. *et al.* Induction of β -cell proliferation and engraftment using a single G1/S regulatory molecule, cdk6. *Diabetes* **59**, 1926–1936 (2010).

Andrew P Morris^{1,140}, Benjamin F Voight^{2,3,140}, Tanya M Teslovich^{4,140}, Teresa Ferreira^{1,140}, Ayellet V Segre^{2,5,6,140}, Valgerdur Steinthorsdottir⁷, Rona J Strawbridge^{8,9}, Hassan Khan¹⁰, Harald Grallert¹¹, Anubha Mahajan¹, Inga Prokopenko^{1,12}, Hyun Min Kang⁴, Christian Dina^{13–15}, Tonu Esko^{16,17}, Ross M Fraser¹⁸, Stavroula Kanoni¹⁹, Ashish Kumar¹, Vasiliki Lagou¹, Claudia Langenberg²⁰, Jian'an Luan²⁰, Cecilia M Lindgren¹, Martina Müller-Nurasyid^{21–23}, Sonali Pechlivanis²⁴, N William Rayner^{1,12}, Laura J Scott⁴, Steven Wiltshire¹, Loic Yengo^{25,26}, Leena Kinnunen²⁷, Elizabeth J Rossin^{2,5,28,29}, Soumya Raychaudhuri^{2,30,31}, Andrew D Johnson³²,

Antigone S Dimas^{1,33,34}, Ruth J F Loos^{20,35–37}, Sailaja Vedantam^{38,39}, Han Chen⁴⁰, Jose C Florez^{5,6,38,41}, Caroline Fox^{32,42}, Ching-Ti Liu⁴⁰, Denis Rybin⁴³, David J Couper⁴⁴, Wen Hong L Kao⁴⁵, Man Li⁴⁵, Marilyn C Cornelis⁴⁶, Peter Kraft^{46,47}, Qi Sun^{46,48}, Rob M van Dam^{46,49}, Heather M Stringham⁴, Peter S Chines⁵⁰, Krista Fischer¹⁶, Pierre Fontanillas², Oddgeir L Holmen⁵¹, Sarah E Hunt¹⁹, Anne U Jackson⁴, Augustine Kong⁷, Robert Lawrence⁵², Julia Meyer²², John R B Perry^{1,53}, Carl G P Platou^{51,54}, Simon Potter¹⁹, Emil Rehnberg⁵⁵, Neil Robertson^{1,12}, Suthesh Sivapalaratnam⁵⁶, Alena Stančáková⁵⁷, Kathleen Stirrups¹⁹, Gudmar Thorleifsson⁷, Emmi Tikkanen^{58,59}, Andrew R Wood⁵³, Peter Almgren⁶⁰, Mustafa Atalay⁶¹, Rafn Benediktsson^{62,63}, Lori L Bonnycastle⁵⁰, Noël Burt², Jason Carey², Guillaume Charpentier⁶⁴, Andrew T Crenshaw², Alex S F Doney^{65,66}, Mozghan Dorkhan⁶⁰, Sarah Edkins¹⁹, Valur Emilsson⁶⁷, Elodie Eury²⁵, Tom Forsen^{68,69}, Karl Gertow^{8,9}, Bruna Gigante⁷⁰, George B Grant², Christopher J Groves¹², Candace Guiducci², Christian Herder⁷¹, Astradur B Hreidarsson⁶³, Jennie Hui^{72–75}, Alan James^{72,76,77}, Anna Jonsson⁶⁰, Wolfgang Rathmann⁷⁸, Norman Klopp¹¹, Jasmina Kravic⁶⁰, Kaarel Krjutškov¹⁶, Cordelia Langford¹⁹, Karin Leander⁷⁰, Eero Lindholm⁶⁰, Stéphane Lobbens²⁵, Satu Männistö⁵⁹, Ghazala Mirza¹, Thomas W Mühleisen^{79,80}, Bill Musk^{72,75,77,81}, Melissa Parkin², Loukianos Rallidis⁸², Jouko Saramies⁸³, Bengt Sennblad^{8,9}, Sonia Shah⁸⁴, Gunnar Sigurðsson^{63,67}, Angela Silveira^{8,9}, Gerald Steinbach⁸⁵, Barbara Thorand⁸⁶, Joseph Trakalo¹, Fabrizio Veglia⁸⁷, Roman Wennauer⁸⁵, Wendy Winckler², Delilah Zabaneh⁸⁴, Harry Campbell^{18,88}, Cornelia van Duijn^{89,90}, Andre G Uitterlinden^{89–91}, Albert Hofman⁸⁹, Eric Sijbrands⁹¹, Goncalo R Abecasis⁴, Katharine R Owen^{12,92}, Eleftheria Zeggini¹⁹, Mieke D Trip⁵⁶, Nita G Forouhi²⁰, Ann-Christine Syvänen⁹³, Johan G Eriksson^{59,68,94,95}, Leena Peltonen¹³⁹, Markus M Nöthen^{79,80}, Beverley Balkau^{96,97}, Colin N A Palmer^{65,66}, Valeriya Lyssenko⁶⁰, Tiinamaija Tuomi^{95,98}, Bo Isomaa^{95,99}, David J Hunter^{46–48}, Lu Qi^{46,48}, Wellcome Trust Case Control Consortium¹⁰⁰, Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) Investigators¹⁰⁰, Genetic Investigation of ANthropometric Traits (GIANT) Consortium¹⁰⁰, Asian Genetic Epidemiology Network–Type 2 Diabetes (AGEN-T2D) Consortium¹⁰⁰, South Asian Type 2 Diabetes (SAT2D) Consortium¹⁰⁰, Alan R Shuldiner^{101–103}, Michael Roden^{71,104}, Ines Barroso^{19,105,106}, Tom Wilsgaard¹⁰⁷, John Beilby^{72–74}, Kees Hovingh⁵⁶, Jackie F Price¹⁸, James F Wilson^{18,88}, Rainer Rauramaa^{108,109}, Timo A Lakka^{61,108}, Lars Lind¹¹⁰, George Dedoussis¹¹¹, Inger Njølstad¹⁰⁷, Nancy L Pedersen⁵⁵, Kay-Tee Khaw¹⁰, Nicholas J Wareham²⁰, Sirkka M Keinänen-Kiukaanniemi^{112,113}, Timo E Saaristo^{114,115}, Eeva Korpi-Hyövähti¹¹⁶, Juha Saltevo¹¹⁷, Markku Laakso⁵⁷, Johanna Kuusisto⁵⁷, Andres Metspalu^{16,17}, Francis S Collins⁵⁰, Karen L Mohlke¹¹⁸, Richard N Bergman¹¹⁹, Jaakko Tuomilehto^{27,116,120,121}, Bernhard O Boehm¹²², Christian Gieger²², Kristian Hveem⁵¹, Stephane Cauchi²⁵, Philippe Froguel^{25,123}, Damiano Baldassarre^{87,124}, Elena Tremoli^{87,124}, Steve E Humphries¹²⁵, Danish Saleheen^{10,126}, John Danesh¹⁰, Erik Ingelsson⁵⁵, Samuli Ripatti^{19,58,59}, Veikko Salomaa⁵⁹, Raimund Erbel¹²⁷, Karl-Heinz Jöckel²⁴, Susanne Moebus²⁴, Annette Peters⁸⁶, Thomas Illig^{11,128}, Ulf de Faire⁷⁰, Anders Hamsten^{8,9}, Andrew D Morris^{65,66}, Peter J Donnelly^{1,129}, Timothy M Frayling⁵³, Andrew T Hattersley¹³⁰, Eric Boerwinkle^{131,132}, Olle Melander⁶⁰, Sekar Kathiresan^{2,5,133}, Peter M Nilsson⁶⁰, Panos Deloukas¹⁹, Unnur Thorsteinsdottir^{7,62}, Leif C Groop⁶⁰, Kari Stefansson^{7,62}, Frank Hu^{46,48}, James S Pankow¹³⁴, Josée Dupuis^{32,40}, James B Meigs^{6,135}, David Altshuler^{2,5,6,136–138,141}, Michael Boehnke^{4,141} & Mark I McCarthy^{1,12,92,141} for the DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium

¹Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK. ²Broad Institute of Harvard and Massachusetts Institute of Technology (MIT), Cambridge, Massachusetts, USA. ³Department of Pharmacology, University of Pennsylvania–Perelman School of Medicine, Philadelphia, Pennsylvania, USA. ⁴Department of Biostatistics, University of Michigan, Ann Arbor, Michigan, USA. ⁵Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts, USA. ⁶Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA. ⁷deCODE Genetics, Reykjavik, Iceland. ⁸Atherosclerosis Research Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden. ⁹Center for Molecular Medicine, Karolinska University Hospital Solna, Stockholm, Sweden. ¹⁰Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. ¹¹Research Unit of Molecular Epidemiology, Helmholtz Zentrum Muenchen, Neuherberg, Germany. ¹²Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK. ¹³Institut National de la Santé et de la Recherche Médicale (INSERM) Unité Mixte de Recherche (UMR) 1087, Nantes, France. ¹⁴Centre National de la Recherche Scientifique (CNRS) UMR 6291, Nantes, France. ¹⁵Department of Biology, Medicine and Health, Nantes University, Nantes, France. ¹⁶Estonian Genome Center, University of Tartu, Tartu, Estonia. ¹⁷Institute of Molecular and Cell Biology, University of Tartu, Tartu, Estonia. ¹⁸Centre for Population Health Sciences, University of Edinburgh, Edinburgh, UK. ¹⁹Wellcome Trust Sanger Institute, Hinxton, Cambridge, UK. ²⁰Medical Research Council (MRC) Epidemiology Unit, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK. ²¹Institute of Medical Informatics, Biometry and Epidemiology, Ludwig-Maximilians-Universität, Munich, Germany. ²²Institute of Genetic Epidemiology, Helmholtz Zentrum Muenchen, Neuherberg, Germany. ²³Department of Medicine I, University Hospital Grosshadern, Ludwig-Maximilians-Universität, Munich, Germany. ²⁴Institute for Medical Informatics, Biometry and Epidemiology, University Hospital of Essen, University Duisburg-Essen, Essen, Germany. ²⁵CNRS UMR 8199, Institute of Biology and Lille 2 University, Pasteur Institute, Lille, France. ²⁶Laboratory of Mathematics, CNRS UMR 8524, University Lille 1, Model for Data Analysis and Learning (MODAL) Team, Institut National de Recherche en Informatique et en Automatique (INRIA) Lille Nord-Europe, Lille, France. ²⁷Diabetes Prevention Unit, National Institute for Health and Welfare, Helsinki, Finland. ²⁸Health Science and Technology MD Program, Harvard

University and Massachusetts Institute of Technology, Boston, Massachusetts, USA. ²⁹Harvard Biological and Biomedical Sciences Program, Harvard University, Boston, Massachusetts, USA. ³⁰Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. ³¹Partners Center for Personalized Genomic Medicine, Boston, Massachusetts, USA. ³²National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, Massachusetts, USA. ³³Department of Genetic Medicine and Development, University of Geneva Medical School, Geneva, Switzerland. ³⁴Biomedical Sciences Research Center Al Fleming, Vari, Greece. ³⁵Charles R Bronfman Institute for Personalized Medicine, Mount Sinai School of Medicine, New York, New York, USA. ³⁶Child Health and Development Institute, Mount Sinai School of Medicine, New York, New York, USA. ³⁷Department of Preventive Medicine, Mount Sinai School of Medicine, New York, New York, USA. ³⁸Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA. ³⁹Division of Genetics and Endocrinology, Children's Hospital, Boston, Massachusetts, USA. ⁴⁰Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA. ⁴¹Diabetes Research Center, Diabetes Unit, Massachusetts General Hospital, Boston, Massachusetts, USA. ⁴²Division of Endocrinology and Metabolism, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. ⁴³Boston University Data Coordinating Center, Boston, Massachusetts, USA. ⁴⁴Collaborative Studies Coordinating Center, Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. ⁴⁵Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. ⁴⁶Department of Nutrition and Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA. ⁴⁷Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA. ⁴⁸Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. ⁴⁹Saw Swee Hock School of Public Health, National University of Singapore, Singapore. ⁵⁰National Human Genome Research Institute, US National Institutes of Health, Bethesda, Maryland, USA. ⁵¹Nord-Trøndelag Health Study (HUNT) Research Centre, Department of Public Health and General Practice, Norwegian University of Science and Technology, Levanger, Norway. ⁵²Centre for Genetic Epidemiology and Biostatistics, The University of Western Australia, Nedlands, Western Australia, Australia. ⁵³Genetics of Complex Traits, Institute of Biomedical and Clinical Science, Peninsula Medical School, University of Exeter, Exeter, UK. ⁵⁴Department of Internal Medicine, Levanger Hospital, Nord-Trøndelag Health Trust, Levanger, Norway. ⁵⁵Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. ⁵⁶Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. ⁵⁷Department of Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland. ⁵⁸Institute for Molecular Medicine Finland (FIMM), Helsinki, Finland. ⁵⁹Department of Chronic Disease Prevention, National Institute for Health and Welfare, Helsinki, Finland. ⁶⁰Department of Clinical Science Malmö, Lund University Diabetes Centre, Scania University Hospital, Lund University, Malmö, Sweden. ⁶¹Institute of Biomedicine, Physiology, University of Eastern Finland, Kuopio, Finland. ⁶²Faculty of Medicine, University of Iceland, Reykjavík, Iceland. ⁶³Department of Endocrinology and Metabolism, Landspítali University Hospital, Reykjavík, Iceland. ⁶⁴Endocrinology-Diabetology Unit, Corbeil-Essonnes Hospital, Corbeil-Essonnes, France. ⁶⁵Diabetes Research Centre, Biomedical Research Institute, University of Dundee, Ninewells Hospital, Dundee, UK. ⁶⁶Pharmacogenomics Centre, Biomedical Research Institute, University of Dundee, Ninewells Hospital, Dundee, UK. ⁶⁷Icelandic Heart Association, Kopavogur, Iceland. ⁶⁸Department of General Practice and Primary Health Care, University of Helsinki, Helsinki, Finland. ⁶⁹Vaasa Health Care Centre, Vaasa, Finland. ⁷⁰Division of Cardiovascular Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. ⁷¹Institute for Clinical Diabetology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany. ⁷²Busseton Population Medical Research Institute, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia. ⁷³PathWest Laboratory Medicine of Western Australia, Queen Elizabeth II Medical Centre, Nedlands, Western Australia, Australia. ⁷⁴School of Pathology and Laboratory Medicine, The University of Western Australia, Nedlands, Western Australia, Australia. ⁷⁵School of Population Health, The University of Western Australia, Nedlands, Western Australia, Australia. ⁷⁶Department of Pulmonary Physiology and Sleep Medicine, West Australian Sleep Disorders Research Institute, Queen Elizabeth II Medical Centre, Nedlands, Western Australia, Australia. ⁷⁷School of Medicine and Pharmacology, University of Western Australia, Nedlands, Western Australia, Australia. ⁷⁸Institute of Biometrics and Epidemiology, German Diabetes Center, Leibniz Center for Diabetes Research at Heinrich Heine University Düsseldorf, Düsseldorf, Germany. ⁷⁹Institute of Human Genetics, University of Bonn, Bonn, Germany. ⁸⁰Department of Genomics, Life & Brain Center, University of Bonn, Bonn, Germany. ⁸¹Respiratory Medicine, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia. ⁸²Department of Cardiology, University General Hospital Attikon, Athens, Greece. ⁸³South Karelia Central Hospital, Lappeenranta, Finland. ⁸⁴Department of Genetics, Evolution and Environment, University College London (UCL) Genetics Institute, University College London, London, UK. ⁸⁵Department of Clinical Chemistry and Central Laboratory, University of Ulm, Ulm, Germany. ⁸⁶Institute of Epidemiology II, Helmholtz Zentrum München, Neuherberg, Germany. ⁸⁷Centro Cardiologico Monzino, IRCCS, Milan, Italy. ⁸⁸MRC Institute of Genetics and Molecular Medicine at the University of Edinburgh, Western General Hospital, Edinburgh, UK. ⁸⁹Department of Epidemiology, Erasmus University Medical Center, Rotterdam, The Netherlands. ⁹⁰Netherlands Genomics Initiative, Netherlands Consortium for Healthy Ageing and Centre for Medical Systems Biology, Rotterdam, The Netherlands. ⁹¹Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands. ⁹²Oxford National Institute for Health Research Biomedical Research Centre, Churchill Hospital, Oxford, UK. ⁹³Molecular Medicine, Department of Medical Sciences, Uppsala University, Uppsala, Sweden. ⁹⁴Unit of General Practice, Helsinki University General Hospital, Helsinki, Finland. ⁹⁵Folkhälsan Research Center, Helsinki, Finland. ⁹⁶INSERM CESP U1018, Villejuif, France. ⁹⁷University Paris Sud 11, UMR5 1018, Villejuif, France. ⁹⁸Department of Medicine, Helsinki University Hospital, University of Helsinki, Helsinki, Finland. ⁹⁹Department of Social Services and Health Care, Jakobstad, Finland. ¹⁰⁰A full list of members is provided in the **Supplementary Note**. ¹⁰¹Division of Endocrinology, Diabetes and Nutrition, University of Maryland School of Medicine, Baltimore, Maryland, USA. ¹⁰²Geriatric Research Education and Clinical Center, Baltimore Veterans Administration Medical Center, Baltimore, Maryland, USA. ¹⁰³Program in Personalized and Genomic Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA. ¹⁰⁴Department of Medicine/Metabolic Diseases, Heinrich Heine University Düsseldorf, Düsseldorf, Germany. ¹⁰⁵University of Cambridge Metabolic Research Laboratories, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK. ¹⁰⁶National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK. ¹⁰⁷Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway. ¹⁰⁸Kuopio Research Institute of Exercise Medicine, Kuopio, Finland. ¹⁰⁹Department of Clinical Physiology and Nuclear Medicine, Kuopio University Hospital, Kuopio, Finland. ¹¹⁰Department of Medical Sciences, Uppsala University, Akademiska Sjukhuset, Uppsala, Sweden. ¹¹¹Department of Dietetics-Nutrition, Harokopio University, Athens, Greece. ¹¹²Faculty of Medicine, Institute of Health Sciences, University of Oulu, Oulu, Finland. ¹¹³Unit of General Practice, Oulu University Hospital, Oulu, Finland. ¹¹⁴Finnish Diabetes Association, Tampere, Finland. ¹¹⁵Pirkanmaa Hospital District, Tampere, Finland. ¹¹⁶Department of Internal Medicine, South Ostrobothnia Central Hospital, Seinäjoki, Finland. ¹¹⁷Department of Medicine, Central Finland Central Hospital, Jyväskylä, Finland. ¹¹⁸Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. ¹¹⁹Diabetes and Obesity Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA. ¹²⁰Red RECAVA Grupo RD06/0014/0015, Hospital Universitario La Paz, Madrid, Spain. ¹²¹Centre for Vascular Prevention, Danube-University Krems, Krems, Austria. ¹²²Division of Endocrinology and Diabetes, Department of Internal Medicine, University Medical Centre Ulm, Ulm, Germany. ¹²³Genomic Medicine, Imperial College London, Hammersmith Hospital, London, UK. ¹²⁴Department of Pharmacological Sciences, University of Milan, Milan, Italy. ¹²⁵Institute of Cardiovascular Science, University College London, London, UK. ¹²⁶Center for Non-Communicable Diseases Pakistan, Karachi, Pakistan. ¹²⁷Clinic of Cardiology, West German Heart Centre, University Hospital of Essen, University Duisburg-Essen, Essen, Germany. ¹²⁸Hannover Unified Biobank, Hannover Medical School, Hannover, Germany. ¹²⁹Department of Statistics, University of Oxford, Oxford, UK. ¹³⁰Diabetes Genetics, Institute of Biomedical and Clinical Science, Peninsula Medical School, University of Exeter, Exeter, UK. ¹³¹Human Genetics Center, University of Texas Health Science Center at Houston, Houston, Texas, USA. ¹³²Human Genome Sequencing Center at Baylor College of Medicine, Houston, Texas, USA. ¹³³Cardiovascular Research Center, Massachusetts General Hospital, Boston, Massachusetts, USA. ¹³⁴Division of Epidemiology and Community Health, University of Minnesota, Minneapolis, Minnesota, USA. ¹³⁵General Medicine Division, Massachusetts General Hospital, Boston, Massachusetts, USA. ¹³⁶Department of Genetics, Harvard Medical School, Boston, Massachusetts, USA. ¹³⁷Department of Molecular Biology, Harvard Medical School, Boston, Massachusetts, USA. ¹³⁸Diabetes Unit, Massachusetts General Hospital, Boston, Massachusetts, USA. ¹³⁹Deceased. ¹⁴⁰These authors contributed equally to this work. ¹⁴¹These authors jointly directed this work. Correspondence should be addressed to A.P.M. (amorris@well.ox.ac.uk), M.B. (boehnke@umich.edu) or M.I.M. (mark.mccarthy@drf.ox.ac.uk).

ONLINE METHODS

Stage 1 meta-analysis. The stage 1 meta-analysis consisted of 12,171 T2D cases and 56,862 controls across 12 GWAS of individuals of European descent (Supplementary Table 1). Samples were typed with a range of GWAS genotyping products. Sample and SNP quality control analyses were undertaken within each study. For each GWAS, up to 2.5 million SNPs were then imputed using CEU samples from Phase 2 of the International HapMap Project²⁹. Each SNP with MAF of >1% passing quality control was tested for association with T2D under an additive model after adjustment for study-specific covariates, including indicators of population structure. The results of each GWAS were corrected for residual population structure using the genomic control inflation factor⁵⁰ and were combined via fixed-effects inverse variance-weighted meta-analysis. The results of the stage 1 meta-analysis were subsequently corrected by genomic control ($\lambda_{GC} = 1.10$).

Stage 2 meta-analysis. The stage 2 meta-analysis consisted of 21,491 T2D cases and 55,647 controls across 25 studies of individuals of European descent and 1,178 T2D cases and 2,472 controls from 1 study of individuals of Pakistani descent (PROMIS) (Supplementary Table 1). All samples were genotyped with the Metabochip. Sample and SNP quality control analyses were undertaken within each study. Each SNP with MAF of >1% passing quality control was tested for association with T2D under an additive model after adjustment for study-specific covariates. We would expect inflation in association signals across the content of the Metabochip, even in the absence of population structure, because this chip has been designed to be enriched for loci associated with T2D and other T2D-related metabolic traits. The results of each study were thus corrected for residual population structure using the genomic control inflation factor obtained from a subset of 3,598 independent QT-interval SNPs (CEU $r^2 < 0.05$), which were not expected to be associated with T2D. The stage 2 meta-analysis was performed in two steps: (i) all studies of individuals of European descent were combined, and (ii) the PROMIS study was added. In both steps, the results of each study were combined via fixed-effects inverse variance-weighted meta-analysis. The results of the stage 2 European meta-analysis were corrected by QT-interval genomic control ($\lambda_{QT} = 1.19$), but this adjustment was not then necessary after the addition of PROMIS ($\lambda_{QT} = 0.99$ was less than 1). Heterogeneity in allelic effects between studies of individuals of European descent and, subsequently, between the European meta-analysis and the PROMIS study was assessed by means of Cochran's Q statistic⁵¹.

Combined meta-analysis. The results of the stage 1 and stage 2 meta-analyses were combined for all Metabochip SNPs via fixed-effects inverse variance-weighted meta-analysis. The combined meta-analysis consisted of 34,840 cases and 114,981 controls. This was performed in two steps: (i) stage 1 meta-analysis with individuals of European descent was combined with stage 2 meta-analysis, and (ii) the PROMIS study was added. The results of the combined European meta-analysis were corrected by QT-interval genomic control ($\lambda_{QT} = 1.13$), but this adjustment was not necessary after the addition of PROMIS ($\lambda_{QT} = 0.98$ was less than 1) (Supplementary Fig. 12). Heterogeneity in allelic effects between the stage 1 and stage 2 meta-analyses was assessed by means of Cochran's Q statistic.

Obtaining meta-analysis results for lead SNPs in GWAS of individuals of south and east Asian descent. We obtained summary statistics (RAFs, association *P* values, allelic ORs and 95% CIs) for lead SNPs at the newly discovered loci in meta-analyses of T2D GWAS in (i) 5,561 cases and 14,458 controls of south Asian descent¹⁰, excluding 1,958 overlapping samples from PROMIS that were also included in our study, comprising 568,976 directly genotyped autosomal SNPs and (ii) 6,952 cases and 11,865 controls of east Asian descent¹¹, comprising 2,626,356 directly genotyped and imputed autosomal SNPs. For each SNP, summary statistics were aligned to the risk allele in our meta-analysis of individuals that were primarily of European descent.

Calculation of sibling relative risk and liability-scale variance explained. Assuming a multiplicative model (within and between variants), the contribution to the sibling relative risk of a set of *N* SNPs is given by

$$\lambda_s = \prod_{j=1}^N \left[1 + \frac{p_j(1-p_j)(\psi_j-1)^2}{2[(1-p_j) + p_j\psi_j]^2} \right]^2$$

where p_j and ψ_j denote the RAF and corresponding allelic OR at the *j*th SNP, respectively⁵². Assuming disease prevalence *K*, the liability-scale variance²⁰ explained by these SNPs is given by

$$h_L^2 = \frac{2 \left[T - T_1 \sqrt{(1 - (T^2 - T_1^2)(1 - T/\omega))} \right]}{\omega + T_1^2(\omega - T)}$$

where $T = \Phi^{-1}(1 - K)$, $T_1 = \Phi^{-1}(1 - \lambda_s K)$ and $\omega = z/K$, with *z* being the height of the standard Gaussian density at *T* and Φ^{-1} denoting the standard Gaussian inverse cumulative distribution function.

Z-score mixture modeling. We considered the distribution of *Z* scores from the stage 2 meta-analysis, aligned to the risk allele from stage 1, at a subset of 3,412 independent T2D replication variants (CEU $r^2 < 0.05$), excluding lead SNPs and proxies (CEU $r^2 \geq 0.1$) at the 63 established and newly discovered susceptibility loci on the Metabochip. The stage 2 *Z* scores were modeled as a mixture of two Gaussian distributions with (i) mean zero and unit variance (under the null hypothesis of no association) and (ii) unknown mean (greater than zero) and variance (under the alternative hypothesis). The mean and variance of the alternative distribution and the mixing proportion were estimated using an expectation-maximization algorithm.

We estimated the posterior probability that each of the 3,412 independent replication SNPs is truly associated with T2D from the mixture distribution. We approximated the contribution of these SNPs to λ_s by simulation from the mixture distribution. For each simulated replicate, we selected 'causal' variants at random from these SNPs according to their posterior probability of association. Over 1,000 replicates, we approximated the mean and 95% CI for (i) the number of causal variants among the 3,412 independent replication SNPs and (ii) the contribution to λ_s , using estimated RAFs and allelic ORs from the stage 2 meta-analysis. For each replicate, we also generated a hypothetical third stage to the study consisting of 100,000 T2D cases and 100,000 controls. For each causal variant, we generated association summary statistics (*Z* score aligned to the risk allele from stage 1) according to the RAF and allelic OR from our stage 2 meta-analysis.

Assessment of allele frequency variation across European populations. We calculated *F* statistics (F_{ST}) across European populations using data from the 1000 Genomes Project (CEU, Toscani in Italia (TSI), Finnish from Finland (FIN), British from England and Scotland (GBR) and Iberian populations in Spain (IBS))¹³ for the subset of SNPs selected for replication on the Metabochip. F_{ST} was calculated by comparing mean heterozygosity across all populations to the mean within each subpopulation, weighted by the number of contributing chromosomes from each subpopulation. We compared F_{ST} for the subset of T2D replication SNPs that were directionally consistent between stage 1 and stage 2 meta-analyses with all Metabochip replication SNPs (up to 65,345 SNPs), using the Kolmogorov-Smirnov test.

False discovery rate analysis. We undertook FDR analysis⁵³ of 64,646 Metabochip replication SNPs using combined meta-analysis *P* values. From this analysis, we observed $\hat{\pi}_0 = 0.88$, consistent with an excess of true positives in this set. We compared these *P* values with FDR *Q* values and posterior probabilities of membership to the alternative distribution from the mixture model (Supplementary Fig. 4) at the set of 2,172 T2D replication SNPs with concordant direction of allelic effect in both stages of the meta-analysis, after exclusion of 11 AT/GC SNPs with obvious strand orientation misalignments. FDR analysis also indicated an excess of expected true positives in this set of SNPs, even at relatively consistent thresholds (for example, we expect 1 false positive and 66 true positives at a *Q* value of 0.014).

Sex-differentiated meta-analysis. The stage 1, stage 2 and combined meta-analyses were repeated for males and females separately, with correction for population structure within each sex (Supplementary Fig. 13). The male-specific meta-analysis consisted of 20,219 cases and 54,604 controls, and the female-specific meta-analysis consisted of 14,621 cases and 60,377 controls. The sex-specific meta-analyses were then combined to conduct a sex-differentiated test of association and a test of heterogeneity in allelic effects between males and females³².

Physiological analyses. We obtained summary statistics (association P values and Z scores for direction of effect or allelic effects and corresponding standard errors) for lead T2D-associated SNPs in the GWAS meta-analyses of metabolic traits in individuals of European descent. Summary statistics were aligned to the T2D risk allele from the combined meta-analysis. We obtained summary statistics for lead SNPs in all newly discovered and established loci for glycemic traits in non-diabetic individuals from the MAGIC Investigators^{5,34}. For fasting glucose and fasting insulin concentrations, the meta-analysis comprised up to 133,010 individuals, either genotyped with GWAS arrays and imputed at up to ~2.5 million SNPs or genotyped with the Metabochip. We also considered surrogate estimates of β -cell function (HOMA-B) and insulin resistance (HOMA-IR) derived by homeostasis model assessment in up to 38,238 individuals (from GWAS meta-analysis only, as these traits were not investigated in the enlarged MAGIC Metabochip study). We obtained summary statistics for lead SNPs in the newly discovered T2D-associated loci (also including *GRB14* and *HMG20A*) for BMI in up to 119,600 individuals from the GIANT Consortium¹⁵. To eliminate potential bias of BMI association on allelic effect estimates at T2D susceptibility loci⁵⁴, we restricted our attention to meta-analysis of population-based studies not ascertained on the basis of disease status for ~2.8 million directly genotyped and/or imputed SNPs. We obtained summary statistics for the same SNPs for plasma lipid concentrations from the Global Lipids Genetics Consortium¹⁶. This meta-analysis comprised ~2.6 million directly genotyped and/or imputed SNPs assessed for association with plasma concentrations of total cholesterol (up to 100,184 individuals), LDL (up to 95,454 individuals), HDL (up to 99,900 individuals) and triglycerides (up to 96,598 individuals).

We also examined T2D association summary statistics at lead SNPs for 37 established T1D susceptibility loci. For each of these SNPs, we reported the allelic OR (aligned to the T2D risk allele) and P values in (i) our stage 1 T2D meta-analysis and (ii) a GWAS meta-analysis of 7,514 T1D cases and 9,045 population controls of European descent from the Type 1 Diabetes Genetics Consortium³⁵.

Expression analyses. We identified proxies ($CEU\ r^2 > 0.8$) for each lead T2D-associated SNP in our newly discovered loci (also including *GRB14* and *HMG20A*). We interrogated public databases and unpublished resources for *cis*-eQTL expression with these SNPs in multiple tissues (details of these resources are summarized in the **Supplementary Note**). The collated results from these resources met study-specific criteria for statistical significance for association with transcript expression. For each transcript associated with a lead T2D SNP (or proxy), we identified the lead *cis*-eQTL SNP and then estimated LD between them, using 1000 Genomes Project data to assess coincidence of the signals.

We subsequently tested for association of each lead T2D SNP with the expression of flanking transcripts (within a 1-Mb window) in 603 subcutaneous adipose tissue samples and 745 peripheral blood samples from individuals from the Icelandic population, genotyped using the Illumina HumanHap300 Bead Array, and imputed up to ~2.5 million SNPs³⁶. We modeled the log-average expression ratio of two fluorophores as a function of the allele count (expected allele count for imputed SNPs) in a linear regression framework, with adjustment for age and sex (and differential cell count for blood samples) as covariates. All P values were also adjusted for the relatedness between individuals by simulating genotypes through the corresponding Icelandic genealogy⁵⁵. We also identified the most strongly associated *cis*-eQTL SNP for each flanking transcript. We then performed a conditional test of association of the transcript with the *cis*-eQTL SNP within the same linear regression framework, with additional adjustment for the lead T2D SNP as a covariate. Conditional analyses determined whether association of the *cis*-eQTL SNP with the transcript could be explained by the lead T2D SNP.

We searched 1000 Genomes Project data (Phase I interim release) for non-synonymous variants in strong LD ($CEU\ r^2 > 0.8$) with lead T2D-associated SNPs in the newly discovered loci (also including *GRB14* and *HMG20A*). Identified nonsynonymous variants were subsequently interrogated for likely downstream functional consequences using SIFT³⁷.

Pathway, text mining and PPI analyses. We generated two lists of transcripts on the basis of the results of the sex-combined and sex-differentiated meta-analyses. The primary list included (i) the nearest transcript to the lead SNP at 41 previously reported common variant loci identified in populations of European descent; (ii) the nearest transcript to the lead SNP at the 10 newly identified

loci ($P < 5 \times 10^{-8}$) from the sex-combined meta-analysis, including *GRB14* and *HMG20A*; (iii) the nearest transcript to the lead SNP at both novel signals ($P < 5 \times 10^{-8}$) from the sex-differentiated meta-analysis; (iv) the nearest transcript to the lead SNP at 6 additional loci with the strongest evidence of association ($P < 5 \times 10^{-7}$) from the sex-combined meta-analysis; and (v) 18 genes implicated in monogenic forms of diabetes³⁸, not already overlapping other loci included in the list. The secondary list incorporated the nearest transcript to the lead SNP at 77 additional loci with posterior probability of association of at least 75% from the mixture model that were not already included in the primary list.

We tested the hypothesis that a PPI network built from the 77 primary transcripts was significantly enriched for physical interaction over and above that expected by chance using DAPPLE⁴¹. To build networks, DAPPLE uses a refined database of high-confidence interactions^{39,40}, which emphasizes confidence of interaction over completeness, with the result that not all proteins are represented. We considered two categories of interactions: direct (between the associated transcripts themselves) and indirect (via common interactors that were not among the associated transcripts). We assessed the significance of the enrichment of physical interactions by permutation. Subsequently, we used the network as a seed to query against the 77 secondary transcripts.

We used GRAIL to highlight genes from T2D susceptibility loci, using similarity of text in PubMed abstracts or in gene ontology-associated codes⁴². To reduce confounding by published T2D GWAS analyses, we restricted our analysis to abstracts published before December 2006. We first tested for enrichment of connectivity in the list of 77 primary transcripts (treating the 18 monogenic loci as a single locus to reduce confounding) and assessed significance via permutation⁴. These gene sets were then used as a seed against which the list of 77 secondary transcripts was queried for connectivity.

We used a two-step GSEA strategy to test for enrichment of transcripts in T2D susceptibility loci in pathways pertaining to 16 biological hypotheses related to disease pathogenesis (full details of these hypotheses are presented in the **Supplementary Note**). In the first step, we applied MAGENTA⁴⁶ to the stage 1 meta-analysis. Genes in each pathway were scored on the basis of the most significant local SNP association using -110 kb and +40 kb boundaries. The 95th percentile of association P values from all genes in the genome was used to determine the enrichment cutoff. In the second 'replication' step, nominally significant gene sets from the first step (MAGENTA $P < 0.05$) were tested for enrichment of T2D association signals in the stage 2 meta-analysis. To account for bias in the Metabochip design for SNPs nominally associated with T2D and related metabolic traits, we used a modified GSEA approach. We tested for enrichment among a broader set of primary or primary and secondary transcripts within LD regions defined by $r^2 > 0.5$ on either side of the lead SNP, extended to the nearest recombination hotspot and then an additional 50 kb (if there was no gene within the LD region, we used the nearest transcript). For robustness testing, we also examined enrichment in the nearest gene to the lead SNPs. The modified GSEA P value was computed as the fraction of randomly sampled sets of loci, matched for number and local gene density to our primary and secondary lists, which have the same or more significant hypergeometric probability as T2D loci. For the null set, we used 1,600 LD-pruned Metabochip T2D replication SNPs with the lowest posterior probability of association (<5%) from the mixture model. To control for potential confounders, we applied the modified GSEA approach to two negative control lists: (i) loci defined by the lowest ranked independent T2D replication SNPs from our stage 2 meta-analysis and (ii) loci for QT-interval on the basis of our stage 2 meta-analysis for independent replication SNPs for this trait, excluding those in our primary and secondary lists of T2D susceptibility loci and those near genes associated with monogenic forms of diabetes.

50. Devlin, B. & Roeder, K. Genomic control for association studies. *Biometrics* **55**, 997–1004 (1999).

51. Ioannidis, J.P. *et al.* Heterogeneity in meta-analyses of genome-wide association investigations. *PLoS ONE* **2**, e841 (2007).

52. Lin, S. *et al.* Exhaustive allelic transmission disequilibrium tests as a new approach to genome-wide association studies. *Nat. Genet.* **36**, 1181–1188 (2004).

53. Storey, J.D. & Tibshirani, R. Statistical methods for identifying differentially expressed genes in DNA microarrays. *Methods Mol. Biol.* **224**, 149–157 (2003).

54. Stolerman, E.S. *et al.* *TCF7L2* variants are associated with increased proinsulin/insulin ratios but not obesity traits in the Framingham Heart Study. *Diabetologia* **52**, 614–620 (2009).

55. Stefansson, H. *et al.* A common inversion under selection in Europeans. *Nat. Genet.* **37**, 129–137 (2005).